Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1807 • ACR Convergence 2020
The Extent of Tubulointerstitial Inflammation in Lupus Nephritis Identifies Two Distinctive Subgroups: Impact on Inflammation Characteristics and Prognosis in Patients with Lupus Nephritis
Sang Jin Lee¹, Eon Jeong Nam¹, Man-Hoon Han² and Yong Jin Kim², ¹Department of Internal Medicine, Kyungpook National University Hospital,, Daegu, Republic of Korea, ²Department of Pathology, Kyungpook National University Hospital,, Daegu, Republic of Korea
Background/Purpose: Lupus nephritis is common clinical manifestation and contributes significantly to mortality in systemic lupus erythematosus (SLE). Recently several studies has been reported that severity of…
Abstract Number: 1824 • ACR Convergence 2020
Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358
Christie Fanton¹, Richard Furie², Neha Dixit¹, Cat Haglund¹, Lin Lu¹, Suresh Siddhanti¹, Vishala Chindalore³, Robert Levin⁴, Isam Diab⁵, Brian Kotzin¹ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Division of Rheumatology, Northwell Health, Great Neck, NY, ³Pinnacle Research Group, Anniston, AL, ⁴Clinical Research of West Florida, Clearwater, FL, ⁵Paramount Medical Research and Consulting, Middleburg Heights, OH
Background/Purpose: Treg dysfunction and impaired IL-2 production have been implicated as key immunological defects in the breakdown of immune self-tolerance in SLE. Low-dose IL-2 can…
Abstract Number: 1841 • ACR Convergence 2020
Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Bizkaia, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone treatment for several autoimmune diseases including Systemic Lupus Erythematosus (SLE). Recently, concerns arose regarding HCQ shortages for SLE patients,…
Abstract Number: 0244 • ACR Convergence 2020
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?
Yiting Wang¹, Kirsten Lum², Karen Costenbader³, Grace Wang⁴, Jennifer Lofland⁵, Dominik Naessens⁶, Yihan Zhao⁷, Kourtney Davis⁸ and Chetan Karyekar⁹, ¹Janssen Research & Development, LLC, Newark, DE, ²Janssen Pharm Technology - Data Sciences and Data Management, Horsham, PA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Janssen Pharmaceuticals, Horsham, ⁵Janssen Global Market Access, horsham, PA, ⁶Jassen Global Market Access, Beerse, Belgium, ⁷Janssen Pharm Technology - Data Sciences and Data Management, Horsham, ⁸Janssen R&D, LLC, Titusville, NJ, ⁹Janssen Global Services, LLC, Horsham, PA
Background/Purpose: SLE is clinically heterogenous and its diagnosis is often difficult or delayed. The length of time from symptom onset or from when patients seek…
Abstract Number: 0260 • ACR Convergence 2020
Does Higher Quality of Care in SLE Improve Quality of Life?
Shilpa Arora¹, Patricia Katz², Jinoos Yazdany³, Joel Block¹, Edward Yelin⁴ and Meenakshi Jolly⁵, ¹Rush University Medical Center, Chicago, IL, ²University of California, San Francisco, Novato, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Rush University, Chicago, IL
Background/Purpose: Disease activity, damage and quality of life (QOL) are core outcomes in Systemic lupus erythematosus (SLE). ER visits and hospital admissions (non-routine health care…
Abstract Number: 0277 • ACR Convergence 2020
Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
Ali Duarte-Garcia¹, Mehmet Hocaoglu², Shirley-Ann Osei-Onomah³, Jesse Dabit¹, Rachel Giblon¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Classification criteria are standardized definitions required to identify well defined cohorts of patients for research. In practice they are also used as a framework…
Abstract Number: 0295 • ACR Convergence 2020
CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
Eunyoung Lee¹, Young-Ho Kim², Hye Won Sim², Eun-Kyung Kang², Yoon-Ho Won², Esther Park², Yeong-Wook Song³ and Kyeong-Man Hong², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²National Cancer Center, Ilsan, Kyonggi-do, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, Korea, Republic of Korea
Background/Purpose: The correlation between the copy number variation of CCL3L1 and susceptibility to systemic lupus erythematosus (SLE), rheumatoid arthritis, Kawasaki disease, and HIV infection has…
Abstract Number: 0441 • ACR Convergence 2020
Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus
Kreager Taber¹, Jessica Williams¹, Weixing Huang², Katherine McLaughlin¹, Christine Vogeli³, Rebecca Cunningham¹, Lisa Wichmann¹ and Candace Feldman⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston
Background/Purpose: The burden of systemic lupus erythematosus (SLE) falls disproportionately on racial/ethnic minorities and individuals of lower socioeconomic status who often receive fragmented, inconsistent care.…
Abstract Number: 0582 • ACR Convergence 2020
Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?
Christine Anastasiou¹, Laura Trupin¹, Patricia Katz², Zara Izadi³, Milena Gianfrancesco¹, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, Novato, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Atherton, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of hospitalization throughout their lifetime, potentially leading to higher patient mortality and healthcare costs.…
Abstract Number: 0843 • ACR Convergence 2020
Rab4A Activation Predisposes to Hepatitis in Spontaneous and Pristane-Induced Mouse Models of Systemic Lupus Erythematosus
Nick Huang¹, Akshay Patel¹, Zachary Oaks¹ and Andras Perl¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: HRES-1/Rab4 or Rab4A, a GTPase responsible for mitochondrial oxidative stress1 and activation of the mechanistic target of rapamycin2, is overexpressed in T cells of…
Abstract Number: 0862 • ACR Convergence 2020
Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE
Teun van Gelder¹, Robert Huizinga², Neil Solomons² and Laura Lisk³, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Shuchi Smita¹, Minjung Kim¹, Maria Chikina¹, Mark Shlomchik¹ and Jeremy Tilstra¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
Abstract Number: 1022 • ACR Convergence 2020
Declining In-hospital Mortality Gap in Lupus Compared to Non-lupus Hospitalizations: A National Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Lupus is a serious, multi-system autoimmune disease that affects young people. Mortality is increased by over 2-3 fold compared to the general population. Time-trends…
Abstract Number: 1259 • ACR Convergence 2020
The Impact of Antimalarial Agents on Traditional and Non-traditional Cardiovascular Markers in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Pamela Munguía-Realpozo², Ivet Etchegaray-Morales² and Socorro Mendez-Martínez¹, ¹Instituto Mexicano del Seguro Social, Puebla, Puebla, Mexico, ²Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico
Background/Purpose: Cardiovascular morbidity and mortality is a well-established problem in patients with systemic lupus erythematosus (SLE). Hydroxychloroquine (HCQ) has been seen as a potential atheroprotective…
Abstract Number: 1276 • ACR Convergence 2020
Using Classification and Regression Tree Analysis to Assess the Construct Validity of the Automated Neuropsychological Assessment Metrics in the Assessment of Cognitive Impairment in SLE Compared to the ACR Neuropsychological Battery
Kimberley Yuen¹, Dorcas Beaton², Kathleen Bingham³, Jiandong Su⁴, Mahta Kakvan⁴, Juan Pablo Diaz-Martinez⁴, Carmela Tartaglia⁵, Lesley Ruttan⁶, Joan Wither⁴, Nicole Anderson⁴, Dennisse Bonilla⁴, May Choi⁷, Marvin Fritzler⁸, Patricia Katz⁹, Robin Green⁶ and Zahi Touma¹⁰, ¹Queen's University School of Medicine; University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, Canada, ²Institute for Work & Health, Toronto, ON, Canada, ³Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁹University of California, San Francisco, Novato, CA, ¹⁰University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is common in systemic lupus erythematosus (SLE) patients, however there is no standard screening tool available. The American College of Rheumatology…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].